AURINIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Aurinia Pharmaceuticals, Inc. and


NEW YORK–(Small business WIRE)–#AUPH–Bragar Eagel & Squire, P.C., a nationally identified stockholder rights regulation agency, reminds traders that a class motion lawsuit has been filed against Aurinia Prescribed drugs, Inc. (“Aurinia” or the “Company”) (NASDAQ: AUPH) in the United States District Court for the Jap District of New York on behalf of all folks and entities who purchased or or else acquired Aurinia securities amongst May 7, 2021 and February 25, 2022, equally dates inclusive (the “Class Period”). Traders have right until June 14, 2022 to use to the Court docket to be appointed as guide plaintiff in the lawsuit.

Simply click listed here to participate in the motion.

Aurinia is a biopharmaceutical enterprise that develops and commercializes therapies to take care of different diseases with unmet health care have to have in Japan and the People’s Republic of China (“China”). The Company’s only merchandise is LUPKYNIS, which it provides for the therapy of grownup sufferers with lively lupus nephritis.

All through the Class Time period, Defendants manufactured materially phony and misleading statements pertaining to the Company’s company, functions, and compliance guidelines. Particularly, Defendants produced wrong and/or misleading statements and/or failed to disclose that: (i) Aurinia was dealing with declining revenues (ii) Aurinia’s 2022 revenue outlook for LUPKYNIS would tumble well small of anticipations (iii) accordingly, the Enterprise experienced considerably overstated LUPKYNIS’s commercial prospective customers (iv) as a result, the Firm experienced overstated its money posture and/or potential customers for 2022 and (v) as a end result, the Company’s general public statements have been materially false and misleading at all applicable times.

On February 28, 2022, Aurinia issued a push launch saying its financial success for the quarter and total calendar year finished December 31, 2021. Amid other goods, Aurinia reported a calendar year-about-yr revenue decrease and announced a reduced-than-envisioned profits outlook for 2022.

On this news, Aurinia’s frequent share price fell $3.94 per share, or 24.26%, to near at $12.30 for every share on February 28, 2022.

As a consequence of Defendants’ wrongful acts and omissions, and the precipitous decrease in the marketplace benefit of the Company’s securities, Plaintiff and other Course associates have endured major losses and damages.

If you procured or otherwise acquired Aurinia shares and endured a decline, are a very long-expression stockholder, have info, would like to discover additional about these promises, or have any queries concerning this announcement or your legal rights or passions with regard to these issues, you should call Brandon Walker or Alexandra Raymond by electronic mail at [email protected], phone at (212) 355-4648, or by filling out this get hold of sort. There is no price tag or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally regarded legislation agency with workplaces in New York and California. The firm represents specific and institutional buyers in industrial, securities, spinoff, and other advanced litigation in point out and federal courts throughout the nation. For a lot more facts about the organization, you should visit Lawyer advertising and marketing. Prior effects do not assurance identical outcomes.


Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Alexandra B. Raymond, Esq.

(212) 355-4648

[email protected]


Resource hyperlink